Pharmacogenomics Guidance Cites Benefits Of Voluntary Submissions
Executive Summary
FDA's final pharmacogenomics guidance outlines the benefits of voluntary pharmaceutical industry submissions of genomic data to the agency
You may also be interested in...
FDA Wants Cardiovascular Adverse Event Data Broadly Available For Research
FDA outlined two proposals to better monitor cardiovascular adverse events, mainly focusing on means to create more comprehensive links between physicians, industry and academia, at a recent Drug Information Association conference
FDA Wants Cardiovascular Adverse Event Data Broadly Available For Research
FDA outlined two proposals to better monitor cardiovascular adverse events, mainly focusing on means to create more comprehensive links between physicians, industry and academia, at a recent Drug Information Association conference
FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain
Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected